Clinical Trials Logo

Nasopharyngeal Carcinoma clinical trials

View clinical trials related to Nasopharyngeal Carcinoma.

Filter by:

NCT ID: NCT02537925 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma

Start date: January 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether celecoxib is effective in the treatment of nasopharyngeal carcinoma by concurrent chemoradiation with weekly nedaplatin.

NCT ID: NCT02523430 Completed - Clinical trials for Nasopharyngeal Carcinoma

HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Nasopharyngeal Carcinoma

Start date: May 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction angiography(DSA) for nasopharyngeal carcinoma.

NCT ID: NCT02512315 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma

Start date: August 2015
Phase: Phase 3
Study type: Interventional

The standard treatment strategy of locally advanced nasopharyngeal carcinoma (NPC) nowadays is concurrent chemoradiation (CCRT) based on intensity-modulated radiation therapy (IMRT). However, distant metastasis remains the major cause of treatment failure, especially in patients with T1-4N2-3M0 diseases (N2-3 NPC). The investigators inferred that it was more appropriate to consider N2-3 NPC as a systemic disease instead of a local disease. NACT of sufficient intensity such as 4 cycles might be effective enough for control of the pre-existing micrometastases. Therefore, the objective of this phase 3 multicenter randomized controlled trial is to make a comparison between NACT of 4 cycles plus CCRT based on IMRT and CCRT alone in N2-3 NPC on distant metastasis, survival and adverse reaction.

NCT ID: NCT02505672 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Vestibular Function After Chemoradiotherapy for Nasopharyngeal Carcinoma

Start date: August 2016
Phase: N/A
Study type: Observational

Nasopharyngeal carcinoma (NPC) is usually treated with chemoradiotherapy. While the effects of this treatment on cochlear function is well characterized, its effect on vestibular function is not well studied. In this study the investigators will study the vestibular function of 50 patients undergoing chemoradiotherapy for NPC both before and after treatment in order to better define its effects. All patients will undergo a validated questionnaire (dizziness handicap index), posturography, audiometry and vestibular-evoked myogenic potentials.

NCT ID: NCT02501993 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma Screening in Zhongshan City

Start date: March 2012
Phase:
Study type: Observational

The primary objective is to determine the early diagnosis rate and mortality rate of the Nasopharyngeal Carcinoma (NPC) in the study population. The secondary objective is to determine the incidence of NPC in the study population.

NCT ID: NCT02500940 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Comparison the Effects of Different Neoadjuvant Chemotherapy Regimen on Acute Toxicity, Tumor Response, and Survival in Patients With Advanced Nasopharyngeal Carcinoma

Start date: May 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the impact of different neoadjuvant chemotherapy schedules of cisplatin and 5-FU on acute toxicity, tumor response, and long-term survival in patients with advanced nasopharyngeal carcinoma

NCT ID: NCT02481089 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Polymorphisms in Key Genes of Glycolytic Pathway: Influence on Radiosensitivity in Nasopharyngeal Carcinoma

Start date: June 2015
Phase: N/A
Study type: Observational

Warburg effect is an important feature of tumors,and genetic variation is one of the main factors of individual differences to radiotherapy treatment response for nasopharyngeal carcinoma(NPC). Through the previous work investigators found that the p53 codon72 (Pro/Arg) was related to the prognosis of NPC; Using the method of proteomics, investigators discovered glycolysis related gene such as PGK1, ALDOA,was associated with radiosensitivity.Thus,with all the previous work,investigators hypothesize that the key gene polymorphisms in glycolytic pathway, such as p53 , influence the glycolytic pathway,which leads to differences in radiosensitivity of NPC. This projects will include 600 cases of patients with NPC to detect common glycolytic key genes polymorphisms. Besides,investigators correlate these factors with their radiosensitivity and prognosis.Then, prediction model will be established, and validation of the prediction model will be done. Using enzyme-labeling instrument ,comet assay and clonogenic assay,cytological experiments will further investigate the influence of key gene polymorphisms on the glycolysis efficiency and mechanism of radiation sensitivity.Thus,investigators could provide theoretical basis of individualized treatment for NPC.

NCT ID: NCT02476669 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Serial Plasma EBV DNA for Nasopharyngeal Carcinoma

Start date: June 2010
Phase:
Study type: Observational

Nasopharyngeal carcinoma (NPC) is an endemic malignancy in Southern China, Hong Kong, Taiwan, Singapore and Malaysia. It is highly associated with Epstein-Barr virus (EBV). Radiation therapy alone is indicated for early stage I to II diseases while concurrent chemoradiation is required for more advanced stage III to IVB diseases. Intensity-modulated radiation therapy (IMRT) is the standard radiation technique for NPC, in virtue of its superior target coverage and dose sparing to adjacent critical organs-at-risks. Plasma EBV DNA and other novel plasma biomarkers have been extensively investigated in NPC. Previous studies have proven their predictive and prognostic values in NPC diagnosis, surveillance and survival outcomes. We would like to investigate the roles of plasma biomarkers including plasma EBV DNA on treatment response evaluation, survival and prognosis on NPC, in the modern era of precision radiation therapy. This will provide important information on refining on the current edition of AJCC/UICC staging classification.

NCT ID: NCT02460887 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT

Start date: June 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to verify that induction gemcitabine and cisplatin plus intensity-modulated radiotherapy (IMRT) is non-inferior to concurrent weekly cisplatin plus IMRT for patients with locoregionally advanced nasopharyngeal carcinoma (NPC).

NCT ID: NCT02460419 Completed - Clinical trials for Nasopharyngeal Carcinoma

Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma

Start date: April 2015
Phase: Phase 3
Study type: Interventional

This multicenter, randomised, phase 3 study is to evaluate the survival benefit of maintenance capecitabine plus best supportive care versus best supportive care for metastatic nasopharyngeal carcinoma patients after disease controlled with TPC palliative chemotherapy.